Video

Dr. Desai on Phase I Study of Entrectinib in Solid Tumors

Ami Vijay Desai, MD, assistant professor of Pediatrics, University of Chicago Comer Children's Hospital, discusses the design of a phase I study testing entrectinib in patients with solid tumors.

Ami Vijay Desai, MD, assistant professor of pediatrics, University of Chicago Comer Children’s Hospital, discusses the design of a phase I study testing entrectinib in patients with solid tumors. She presented these findings at the 2018 ASCO Annual Meeting.

The trial followed a 3+3 dose escalation format and investigated 4 dose levels, Desai says. Researchers were able to escalate to the fourth dose level—at the third level, there was 1 dose-limiting toxicity of increased creatinine for >7 days. At the fourth level, there were 3 dose-limiting toxicities across 2 patients. Desai says these toxicities were reversible on discontinuation of drug.

Phase I data suggest the recommended dose level of entrectinib for pediatric patients is 550 mg/m2, according to Desai.

Related Videos
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center